Jan 10, 2020
Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer
Dec 20, 2019
Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool
Dec 09, 2019
Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Dec 03, 2019
Relmada Therapeutics Announces Pricing of Public Offering of Common Stock
Dec 03, 2019
Relmada Therapeutics Announces Proposed Public Offering of Common Stock
Nov 19, 2019
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Relmada Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Oct 17, 2019
Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18
Oct 15, 2019
Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression
Oct 14, 2019
Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15
Oct 10, 2019
Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market
Oct 08, 2019
Relmada Therapeutics Announces Uplisting to The NASDAQ Capital Market
Sep 27, 2019
Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
Jul 29, 2019
Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression
Jun 03, 2019
Relmada Therapeutics to Present at LD Micro Invitational Conference in Los Angeles
May 31, 2019
Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting
Apr 16, 2019
Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results
Apr 03, 2019
Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations
Oct 02, 2018
Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels
Sep 18, 2018
Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder
Aug 09, 2018
Relmada Therapeutics Allowed Patent Application in China Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms